The IPO Window Stays Open, but the Plumbing Beneath It Is Being Rewritten

The U.S. IPO market enters August with momentum and a pipeline, but the regulatory ground underneath it is shifting in ways that will matter long after this week’s deals price.

A Record Second Quarter Sets the Table

The second quarter of 2026 produced 48 IPOs that raised a record-breaking $104.8 billion in proceeds, led by SpaceX’s $75 billion listing — a single deal larger than all U.S. IPOs from the prior two calendar years combined^[1]. Even excluding SpaceX, the quarter would have been the biggest for IPO proceeds since 2021, with nine other deals raising $1 billion or more, including AI chipmaker Cerebras^[1].

Year to date, Renaissance Capital counts 87 IPOs priced with $142.5 billion in total proceeds^[2]. The Renaissance IPO Index is up 14.8% year to date, outpacing the S&P 500’s 9.4% gain^[3]. The deal count is down 26.9% from the prior year, but the average deal size has ballooned, reflecting a market dominated by large, later-stage companies coming public^[2].

Morgan Stanley’s capital markets team noted earlier this year that the 2026 IPO market is distinguished by its scale and breadth, with larger and later-stage companies entering the pipeline across multiple sectors^[2].

The August IPO Lineup: Biotech-Dominant

Four IPOs are currently scheduled for the week of August 4, and the calendar is overwhelmingly biotech^[3]:

Collectively, the three biotechs — Attovia, Braveheart, and Vogenx — are seeking more than $500 million^[4]. All three filed their IPO paperwork within a day of each other in mid-July and have moved in lockstep toward pricing, suggesting coordinated underwriter timing to capitalize on an open window^[4].

Braveheart Bio is the largest of the trio, targeting a $1.4 billion market cap with a lead candidate licensed from China’s Hengrui Pharmaceuticals for hypertrophic cardiomyopathy, positioning it to compete with Bristol Myers Squibb^[3]. Attovia’s ATTOBODY platform targets validated immune pathways, with its lead drug going after IL-31 for chronic pruritus and atopic dermatitis, a space currently dominated by Sanofi and Regeneron’s Dupixent^[3]. Vogenx, the smallest, is developing an oral SGLT1 inhibitor for post-bariatric hypoglycemia and gastroparesis^[3].

River City Bank, a California commercial bank founded in 1973, rounds out the calendar with a $136 million raise. Roughly 90% of its loan portfolio is commercial real estate lending^[3].

The Recent IPO Scorecard: Mixed Signals

The most recent IPOs offer a mixed read on appetite.

Jersey Mike’s (JMKE) — The Blackstone-backed sandwich chain raised $1.0 billion by offering 43.5 million shares at $23, the midpoint of its $21–$25 range^[5]. But 68% of the deal was secondary shares from existing holders, meaning most proceeds went to selling stockholders rather than the company^[5]. Shares opened 8.7% below the offering price on their first day of trading on the NYSE and closed down approximately 6%^[5]. The debut was among the largest-ever initial fundraises for a restaurant IPO, but the break below issue price was an unwelcome signal for consumer-sector new issuance.

Ionic Digital (IOND) — The bitcoin miner and AI infrastructure company, formed from the assets of Celsius Mining, went public via a direct listing on Nasdaq on July 28. Shares surged roughly 26% on debut, reaching a market valuation of about $2.8 billion^[6]. The direct listing format — no underwriters, no new capital raised — gave Celsius Network claimholders an exit route and demonstrated that the alternative-listing pathway remains viable for companies seeking liquidity without dilution^[6].

SpaceX (SPCX) — The $75 billion June IPO remains the defining event of the 2026 market. Shares rose 19% on day one, but the stock has since retreated to approximately $131, below the $135 IPO price, hitting all-time lows in late July^[7]. The pullback coincided with an aborted Starship launch attempt^[7].

The SpaceX Lock-Up Cliff

The most immediate supply overhang in the market is SpaceX’s lock-up expiration, which is staggered around the company’s first earnings report as a public company.

SpaceX will report Q2 2026 results after market close on Tuesday, August 4^[7]. Two days later, on August 6, approximately 911.5 million shares — 20% of locked-up stock — will enter the tradable float^[7]. An additional 10% tranche is scheduled to release subsequently, bringing the total unlock to over 1.37 billion shares^[7].

This is a meaningful supply event. The lock-up release will more than double the tradable float and could test the stock’s price discovery mechanism in its early weeks as a public company^[3]. Morningstar noted that as the number of available shares rises, the weighting of SpaceX in index funds will likely increase significantly, potentially providing a partial offset to selling pressure as passive vehicles adjust their holdings^[7].

The Bigger Story: SEC Proposes Rescinding the Trade-Through Rule

While the IPO pipeline commands headlines, the most consequential development for every U.S. equity investor is the SEC’s June 11 proposal to rescind Rule 611 (the Order Protection Rule, also known as the trade-through rule) and Rule 610(e) (the prohibition on locked and crossed markets) of Regulation NMS^[8][9].

If adopted, this would represent the most significant change to U.S. equity market structure since Regulation NMS was adopted in 2005^[10].

What Rule 611 Does

Rule 611 requires trading centers — exchanges, ATSs, OTC market makers, and broker-dealers that execute orders internally — to establish policies and procedures designed to prevent executions at prices worse than “protected quotations” displayed at other venues^[10]. In practice, this means a broker-dealer cannot internally execute a buy order at $5.02 if another exchange is displaying an offer at $5.01, without first attempting to access that better price^[10].

The SEC’s Rationale for Rescission

Chairman Paul Atkins, who voted against Regulation NMS as a commissioner in 2005, argues the framework was designed for a different technological era^[9]. The Commission offers three principal rationales^[10]:

1. Market forces should shape structure. Removing Rule 611’s restrictions would “empower market participants to compete on merit and innovation.”
2. Rule 611 has had adverse consequences. The SEC identifies market complexity, exchange proliferation, fragmentation of displayed liquidity, increased costs, and proliferation of complex order types as harmful side effects.
3. The rule is no longer necessary. Today’s markets are highly automated and interconnected, routing technology is widely available, and broker-dealer best execution obligations provide sufficient investor protection without a regulatory backstop.

Who Wins, Who Loses

The proposal has asymmetric effects across market participants^[10]:

• Large broker-dealers and wholesalers gain greater flexibility to internalize order flow and design routing strategies that weight factors beyond displayed price.
• Institutional investors may benefit from reduced information leakage and lower costs of sourcing liquidity across fragmented venues — a long-standing complaint about Rule 611.
• Smaller exchanges that currently benefit from protected-quote status could face reduced order flow, as trading centers would no longer be required to access their quotations.
• Retail investors face the most uncertain outcome. Rule 611’s core purpose was ensuring retail orders received the best displayed prices. The SEC acknowledges that removing this protection could have “a greater impact on retail investors,” and the effect on execution quality, fill rates, and prices “remains uncertain”^[10].

Rule 610(e) and Locked/Crossed Markets

The companion proposal would rescind the prohibition on locked and crossed quotations. Exchanges would remain free to maintain their own restrictions or experiment with different quoting practices, potentially leading to greater variation among venues in how locked markets are managed^[10].

The Tick-Size and Access-Fee Delay

In a separate action the same day, the SEC extended the compliance date for the 2024 Regulation NMS amendments on minimum pricing increments (tick sizes) and access fee caps by one year, moving implementation from November 2026 to November 2027^[9]. The Commission cited the cumulative impact of multiple market-structure initiatives — Rule 605 implementation, expanded trading hours, and other technology changes — as justification for the delay^[9].

Timeline

The public comment period runs for 60 days from publication in the Federal Register on June 17, 2026, meaning comments are due in mid-August 2026^[9]. The SEC has received over 300 comment letters to date^[11]. Given the significance of the proposal, significant revisions before a final rule are possible^[10].

Secondaries, Buybacks, and the Issuance Tug-of-War

The issuance picture extends beyond IPOs. BASF announced a €1.0 billion share buyback program starting in August 2026, part of a larger €4 billion repurchase plan announced in September 2024^[12]. REGENXBIO filed a $100 million secondary offering in mid-July^[12]. Baidu called an August extraordinary meeting to seek new share issuance and buyback mandates from shareholders, a dual-track signal of capital-management intent^[12].

The tension between new issuance (which dilutes existing holders) and buybacks (which absorb supply) is a constant in the market’s plumbing, and August’s calendar shows both forces operating simultaneously.

What to Watch Next

1. SpaceX earnings (August 4, after close) and lock-up release (August 6). The first public financial disclosure and the first major float expansion will set the tone for the stock’s early trading life. Watch Starlink subscriber growth, capital expenditure on AI infrastructure, and any guidance commentary. The 911-million-share unlock on August 6 is the immediate supply test.

2. August IPO pricings. Four deals are on the calendar. Biotech IPOs are risk-sensitive to broader market conditions; a sharp pullback in the Nasdaq Biotech Index could compress ranges or trigger postponements. Jersey Mike’s break below issue price is a cautionary data point for consumer deals, though the restaurant sector and biotech sector are not directly comparable.

3. Reg NMS comment period closing. With comments due in mid-August, the next 30 days will reveal how exchanges, wholesalers, ATS operators, and institutional investors position themselves on the trade-through rule’s future. Watch for whether industry consensus forms around rescission with conditions (e.g., enhanced best-execution guidance) or splits into competing camps.

4. Tick-size and access-fee implementation timeline. The one-year delay to November 2027 removes a near-term operational catalyst but leaves the eventual framework in play. Market participants building compliance infrastructure for the 2024 amendments now have additional runway.

5. Secondary offering flow. The REGENXBIO follow-on and Baidu’s shareholder meeting are discrete events, but the broader pace of secondaries versus buybacks is a read on whether companies and insiders are drawing capital from or returning capital to the market.

The base case is that the IPO window remains open through August — the pipeline is real, the index of recent IPOs is outperforming the broad market, and underwriters are testing demand with biotech-heavy deals that historically clear in late summer. The forecast uncertainty sits in two places: the immediate supply shock from SpaceX’s lock-up cliff, and the medium-term market-structure rewiring that the SEC’s Reg NMS proposal would trigger if it moves from proposal to rule. Both are worth tracking with more granularity than the headline IPO calendar suggests.